Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' FRYE RF' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 54 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Alkharfy, KM; Frye, RF
      High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes

      JOURNAL OF CHROMATOGRAPHY B
    2. Hutzler, JM; Frye, RF; Korzekwa, KR; Branch, RA; Huang, SM; Tracy, TS
      Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone

      EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    3. Manley, HJ; Bailie, GR; Frye, RF; McGoldrick, MD
      Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients

      PERITONEAL DIALYSIS INTERNATIONAL
    4. Sowinski, KM; Mueller, BA; Grabe, DW; Manley, HJ; Frye, RF; Bailie, GR; Marx, MA
      Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers

      AMERICAN JOURNAL OF KIDNEY DISEASES
    5. Dowling, TC; Frye, RF; Fraley, DS; Matzke, GR
      Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine

      KIDNEY INTERNATIONAL
    6. Hutzler, JM; Frye, RF; Tracy, TS
      Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma

      JOURNAL OF CHROMATOGRAPHY B
    7. Rosen, DA; Morris, JL; Rosen, KR; Nelson, ER; Steelman, RJ; Gustafson, RA; Wilhelm, JA; Chang, CT; Thackara, JW; Frye, RF
      Nalmefene to prevent epidural narcotic side effects in pediatric patients:A pharmacokinetic and safely study

      PHARMACOTHERAPY
    8. Matzke, GR; Frye, RF; Joy, MS; Palevsky, PM
      Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis

      PHARMACOTHERAPY
    9. Matzke, GR; Frye, RF; Early, JJ; Straka, RJ; Carson, SW
      Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity

      PHARMACOTHERAPY
    10. Frye, RF; Kroboth, PD; Kroboth, FJ; Stone, RA; Folan, M; Salek, FS; Pollock, BG; Linares, AM; Hakala, C
      Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adults

      JOURNAL OF CLINICAL PHARMACOLOGY
    11. Matzke, GR; Frye, RF; Joy, MS; Palevsky, PM
      Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    12. Alkharfy, KM; Kellum, JA; Frye, RF; Matzke, GR
      Effect of ceftazidime on systemic cytokine concentrations in rats

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    13. Branch, RA; Adedoyin, A; Frye, RF; Wilson, JW; Romkes, M
      In vivo modulation of CYP enzymes by quinidine and rifampin

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    14. Dowling, TC; Frye, RF
      Determination of famotidine in human plasma and urine by high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    15. Manley, HJ; Bailie, GR; Asher, RD; Eisele, G; Frye, RF
      Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients

      PERITONEAL DIALYSIS INTERNATIONAL
    16. Dowling, TC; Frye, RF; Fraley, DS; Matzke, GR
      Comparison of iothalamate clearance methods for measuring GFR

      PHARMACOTHERAPY
    17. Grabe, DW; Bailie, GR; Eisele, G; Frye, RF
      Pharmacokinetics of intermittent intraperitoneal ceftazidime

      AMERICAN JOURNAL OF KIDNEY DISEASES
    18. Kroboth, PD; Salek, FS; Pittenger, AL; Fabian, TJ; Frye, RF
      DHEA and DHEA-S: A review

      JOURNAL OF CLINICAL PHARMACOLOGY
    19. Frye, RF; Tammara, B; Cowart, TD; Bramer, SL
      Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone

      JOURNAL OF CLINICAL PHARMACOLOGY
    20. DOWLING TC; FRYE RF; ZEMAITIS MA
      SIMULTANEOUS DETERMINATION OF P-AMINOHIPPURIC ACID, ACETYL-P-AMINOHIPPURIC ACID AND IOTHALAMATE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Journal of chromatography B. Biomedical sciences and applications
    21. FRYE RF; STIFF DD; BRANCH RA
      A SENSITIVE METHOD FOR THE SIMULTANEOUS DETERMINATION OF CAFFEINE ANDITS DIMETHYLXANTHINE METABOLITES IN HUMAN PLASMA - APPLICATION TO CYP1A2 PHENOTYPING

      Journal of liquid chromatography & related technologies
    22. MURPHY JE; AUSTIN ML; FRYE RF
      EVALUATION OF GENTAMICIN PHARMACOKINETICS AND DOSING PROTOCOLS IN 195NEONATES

      American journal of health-system pharmacy
    23. ADEDOYIN A; FRYE RF; MAURO K; BRANCH RA
      CHLOROQUINE MODULATION OF SPECIFIC METABOLIZING ENZYMES ACTIVITIES - INVESTIGATION WITH SELECTIVE 5 DRUG COCKTAIL

      British journal of clinical pharmacology
    24. Adedoyin, A; Frye, RF; Mauro, K; Branch, RA
      Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail (vol 46, pg 215, 1998)

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    25. MARX MA; FRYE RF; MATZKE GR; GOLPER TA
      CEFAZOLIN AS EMPIRIC THERAPY IN HEMODIALYSIS-RELATED INFECTIONS - EFFICACY AND BLOOD-CONCENTRATIONS

      American journal of kidney diseases
    26. JOY MS; MATZKE GR; FRYE RF; PALEVSKY PM
      DETERMINANTS OF VANCOMYCIN CLEARANCE BY CONTINUOUS VENOVENOUS HEMOFILTRATION AND CONTINUOUS VENOVENOUS HEMODIALYSIS

      American journal of kidney diseases
    27. FRYE RF; ADEDOYIN A; MAURO K; MATZKE GR; BRANCH RA
      USE OF CHLORZOXAZONE AS AN IN-VIVO PROBE OF CYTOCHROME-P450 2E1 - CHOICE OF DOSE AND PHENOTYPIC TRAIT MEASURE

      Journal of clinical pharmacology
    28. BURCKART GJ; FRYE RF; KELLY P; BRANCH RA; JAIN A; FUNG JJ; STARZL TE; VENKATARAMANAN R
      INDUCTION OF CYP2E1 ACTIVITY IN LIVER-TRANSPLANT PATIENTS AS MEASUREDBY CHLORZOXAZONE 6-HYDROXYLATION

      Clinical pharmacology and therapeutics
    29. FRYE RF; BERTZ RJ; GRANNEMAN GR; LAUVA I; LAMM J; DENNIS S; VALDES J
      EFFECT OF RITONAVIR ON CYP1A2, 2C19, AND 2E1 ACTIVITIES IN-VIVO

      Clinical pharmacology and therapeutics
    30. ADEDOYIN A; TRUMP DL; BRUFSKY A; FRYE RF; HOFACKER J; BRANCH RA
      SELECTIVE ALTERATION OF SPECIFIC METABOLIZING ENZYME-ACTIVITIES BY DISULFIRAM AND KETOCONAZOLE

      Clinical pharmacology and therapeutics
    31. GLEASON PP; FRYE RF; OTOOLE T
      DEBILITATING REACTION FOLLOWING THE INITIAL DOSE OF TRAMADOL

      The Annals of pharmacotherapy
    32. MARX MA; FRYE RF; MATZKE GR; GOLPER TA
      CEFAZOLIN FOR EMPIRIC TREATMENT OF HD-RELATED INFECTIONS - EFFICACY AND BLOOD-CONCENTRATIONS

      Journal of the American Society of Nephrology
    33. MATZKE GR; FRYE RF
      DRUG ADMINISTRATION IN PATIENTS WITH RENAL-INSUFFICIENCY - MINIMIZINGRENAL AND EXTRARENAL TOXICITY

      Drug safety
    34. FRYE RF; MATZKE GR; ADEDOYIN A; PORTER JA; BRANCH RA
      VALIDATION OF THE 5-DRUG PITTSBURGH COCKTAIL APPROACH FOR ASSESSMENT OF SELECTIVE REGULATION OF DRUG-METABOLIZING-ENZYMES

      Clinical pharmacology and therapeutics
    35. DOWLING TC; FRYE RF; MATZKE GR; FRALEY DS
      PAH RENAL CLEARANCE AFTER AN IV BOLUS IS NOT AN ACCURATE MARKER OF ERPF

      Clinical pharmacology and therapeutics
    36. DOWLING TC; FRYE RF; MATZKE GR; FRALEY DS; RABINOVITZ M
      REDUCED ACETYLATION OF PAH IN LIVER-DISEASE

      Clinical pharmacology and therapeutics
    37. FRYE RF; MATZKE GR; SCHADE R; DIXON R; RABINOVITZ M
      EFFECTS OF LIVER-DISEASE ON THE DISPOSITION OF THE OPIOID ANTAGONIST NALMEFENE

      Clinical pharmacology and therapeutics
    38. FRYE RF; STIFF DD
      DETERMINATION OF CHLORZOXAZONE AND 6-HYDROXYCHLORZOXAZONE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Journal of chromatography B. Biomedical applications
    39. FRYE RF; BRANCH RA
      IMPROVED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF DEBRISOQUINE AND 4-HYDROXYDEBRISOQUINE IN HUMAN URINE FOLLOWING DIRECT-INJECTION

      Journal of chromatography B. Biomedical applications
    40. MATZKE GR; FRYE RF; JOY MS; PALEVSKY P
      DETERMINANTS OF CEFTRIAXONE CLEARANCE BY CVVHD AND CVVH

      Journal of the American Society of Nephrology
    41. MATZKE GR; JOY MS; FRYE RF; PALEVSKY P
      CLEARANCE OF CEFTAZIDIME (TAZ) BY CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH) AND HEMODIALYSIS (CVVHD)

      Journal of the American Society of Nephrology
    42. DOWLING TC; FRYE RF; MATZKE GR; FRALEY DS
      RENAL CLEARANCES OF AMINOHIPPURATE AND ITS ACETYLATED METABOLITE IN PATIENTS WITH LIVER-DISEASE

      Journal of the American Society of Nephrology
    43. FRYE RF; MATZKE GR; JALLAD NS; WILHELM JA; BIKHAZI GB
      THE EFFECT OF AGE ON THE PHARMACOKINETICS OF THE OPIOID ANTAGONIST NALMEFENE

      British journal of clinical pharmacology
    44. MATZKE GR; FRYE RF; ALEXANDER ACM; REYNOLDS R; DIXON R; JOHNSTON J; RAULT RM
      THE EFFECT OF RENAL-INSUFFICIENCY AND HEMODIALYSIS ON THE PHARMACOKINETICS OF NALMEFENE

      Journal of clinical pharmacology
    45. KARARA AH; FRYE RF; HAYES PE; WEAVER ML; ROBINSON WT; RAULT RM; MATZKE GR
      PHARMACOKINETICS OF ABECARNIL IN PATIENTS WITH RENAL-INSUFFICIENCY

      Clinical pharmacology and therapeutics
    46. KELLY PA; FRYE RF; BURCKART GJ; LEVER J; VENKATARAMANAN RV; FUNG JJ; MATZKE GR; BRANCH RA
      DIFFERENTIAL CYP450 ISOZYME ACTIVIN FOLLOWING ORTHOTOPIC LIVER-TRANSPLANTATION (OLTX)

      Clinical pharmacology and therapeutics
    47. FRYE RF; MATZKE GR; PALEVSKY P; RAULT R
      IMPAIRED 6-HYDROXYCHLORZOXAZONE ELIMINATION IN PATIENTS WITH RENAL-INSUFFICIENCY - IMPLICATION FOR PHARMACOGENETIC STUDIES

      Clinical pharmacology and therapeutics
    48. ALEXANDER ACM; MATZKE GR; FRYE RF; BRUNS F; RAULT R
      DIFFERENTIAL RESPONSE OF SERUM IRON INDEXES (SII) TO IRON DEXTRAN (ID) IN HEMODIALYSIS-PATIENTS

      Clinical pharmacology and therapeutics
    49. FRYE RF; MATZKE GR; ALEXANDER ACM; PALEVSKY P; RAULT R; BRANCH RA
      EFFECT OF RENAL-INSUFFICIENCY ON CYP ACTIVITY

      Clinical pharmacology and therapeutics
    50. FRYE RF; MAURO K; ADEDOYIN A; MATZKE GR; BRANCH RA
      NONLINEAR PHARMACOKINETICS OF CHLORZOXAZONE IN HUMANS

      Clinical pharmacology and therapeutics
    51. MATZKE GR; KARARA A; HAYES P; FRYE RF; ALEXANDER AC; WEAVER ML; ROBINSON WT; JOHNSTON J; RAULT R
      EFFECT OF RENAL-INSUFFICIENCY ON THE PHARMACOKINETICS OF ABECARNIL

      Clinical pharmacology and therapeutics
    52. MATZKE GR; ALEXANDER ACM; FRYE RF; REYNOLDS R; WHITMAN C; DIXON RB; RAULT R
      THE DISPOSITION OF NALMEFENE IS SIGNIFICANTLY ALTERED IN PATIENTS WITH END-STAGE RENAL-DISEASE

      Clinical pharmacology and therapeutics
    53. MATZKE GR; COMSTOCK T; FRYE RF; WEINER M; CARTER W
      COMPUTERIZED BAYESIAN PHARMACODYNAMIC MODELING FOR ERYTHROPOIETIN DOSAGE INDIVIDUALIZATION

      Journal of the American Society of Nephrology
    54. KISOR DF; FRYE RF; KUDSK KA
      ESTIMATION OF THE HEPATIC EXTRACTION RATIO OF INDOCYANINE GREEN IN SWINE

      Clinical science


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/08/20 alle ore 01:54:51